Search

Dipotassium phosphate

Dipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.

Dinutuximab

Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. … neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

Quinidine

This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. … Quinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species.

Golimumab

treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe … ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.

Sodium phosphate, monobasic, unspecified form

Fibroblast growth factor-1

Anakinra

Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. … A few studies have evaluated the use of anakinra for the treatment of coronavirus disease 2019 (COVID-19).

Enfortumab vedotin

[L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December

Cariprazine

[A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT_1A receptors and as an antagonist at serotonin 5-HT_2A receptors. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.

Cosibelimab

Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the